GH Research Held 350.6 Million Dollars in Cash and Marketable Securities at September 30: Research Spending of 10.1 Million Dollars and a Net Loss of 12.5 Million Dollars
Clinical-stage biopharmaceutical company GH Research reported financial results for the quarter ended September 30, 2026 and provided a business update on November 13, 2026. All figures below are from the body of the company's results release, and this report offers no investment advice.
Cash, cash equivalents and marketable securities were 350.6 million dollars as of September 30, 2026, compared to 280.7 million dollars as of December 31, 2025.
Research and development expenses were 10.1 million dollars for the quarter, compared to 10.6 million dollars for the same quarter in 2025. Net loss was 12.5 million dollars, or 0.18 dollars per share, compared to a net loss of 14.0 million dollars, or 0.23 dollars per share, in the same quarter of 2025.
On the business side, the company said final results of its Phase 1 trial GH001-HV-106 support going from three doses to one dose per treatment visit with its novel aerosol delivery system, that it has received positive initial FDA feedback on its pivotal program in treatment-resistant depression with an End-of-Phase 2 meeting expected in the first quarter of 2027, and that Vanina Popova, M.D., formerly of clinical development at Johnson and Johnson, was appointed chief development officer.
Source: GH Research
Published by GSM · USA (original Chinese edition)
Photo: 图：爱尔兰都柏林航拍（GH Research相关资料图）。Dronepicr，CC BY 3.0，Wikimedia Commons。 / Photo: 爱尔兰都柏林航拍. Dronepicr, CC BY 3.0, via Wikimedia Commons.
British Insurer Aviva Reports Its Third Quarter 2026 Trading Update: General Insurance Premiums of 11.8 Billion Pounds, Up 19 Percent, a Combined Operating Ratio of 93.8 Percent and a Solvency II Cover Ratio of 179 Percent2026-11-14
Questerre Third-Quarter Production Averages 4,634 Barrels of Oil Equivalent per Day: Petroleum and Natural Gas Revenue of 50.8 Million Canadian Dollars and a Net Loss of 27.6 Million Canadian Dollars as the PX Energy Turnaround Finishes on Schedule, Released November 122026-11-14